JP2019527740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527740A5 JP2019527740A5 JP2018566546A JP2018566546A JP2019527740A5 JP 2019527740 A5 JP2019527740 A5 JP 2019527740A5 JP 2018566546 A JP2018566546 A JP 2018566546A JP 2018566546 A JP2018566546 A JP 2018566546A JP 2019527740 A5 JP2019527740 A5 JP 2019527740A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- modified dextran
- complex according
- dextran complex
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000004697 chelate complex Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 2
- -1 guanidine compound Chemical class 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000000683 abdominal cavity Anatomy 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical group [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000002476 tumorcidal effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20165515 | 2016-06-22 | ||
| FI20165515A FI127538B (en) | 2016-06-22 | 2016-06-22 | MODIFIED Dextran Conjugates |
| PCT/EP2017/064929 WO2017220488A1 (en) | 2016-06-22 | 2017-06-19 | Modified dextran conjugates comprising a lysine-urea-glutamate pharmacophore |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527740A JP2019527740A (ja) | 2019-10-03 |
| JP2019527740A5 true JP2019527740A5 (enExample) | 2020-05-21 |
| JP6944720B2 JP6944720B2 (ja) | 2021-10-06 |
Family
ID=59269989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566546A Active JP6944720B2 (ja) | 2016-06-22 | 2017-06-19 | リジン−尿素−グルタメートファーマコフォアを含む修飾デキストラン複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190175767A1 (enExample) |
| EP (1) | EP3475311B1 (enExample) |
| JP (1) | JP6944720B2 (enExample) |
| CN (1) | CN109312004A (enExample) |
| AU (1) | AU2017283151A1 (enExample) |
| CA (1) | CA3027920C (enExample) |
| FI (1) | FI127538B (enExample) |
| IL (1) | IL263886B2 (enExample) |
| WO (1) | WO2017220488A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL240772B1 (pl) * | 2018-06-11 | 2022-06-06 | Nanothea Spolka Akcyjna | Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii |
| EP3636635A1 (en) | 2018-10-11 | 2020-04-15 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Imaging agents |
| US20220324898A1 (en) * | 2019-02-14 | 2022-10-13 | Deutsches Krebsforschungszentrum | Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linker |
| WO2020188318A1 (en) * | 2019-03-19 | 2020-09-24 | Nanothea S.A. | Process of preparing polymeric nanoparticles that chelate radioactive isotopes and have a surface modified with specific molecules targeting the psma receptor and their use |
| CN112209970B (zh) * | 2020-10-21 | 2021-10-29 | 北京师范大学 | 一种锝-99m标记含异腈的谷氨酸-脲衍生物的制备方法和应用 |
| EP4688831A1 (en) * | 2023-03-30 | 2026-02-11 | Genequantum Healthcare (Suzhou) Co., Ltd. | Disaccharide linker, linker-payload containing the same and glycan chain-remodeled antibody-drug conjugate, preparation method and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822594A (en) * | 1987-01-27 | 1989-04-18 | Gibby Wendell A | Contrast enhancing agents for magnetic resonance images |
| SE9803482D0 (sv) | 1998-10-13 | 1998-10-13 | Anders Holmberg | Ion exchange tumor targeting (IETT) |
| CA2669127C (en) * | 2006-11-08 | 2016-09-13 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
| FI119513B (fi) * | 2007-03-07 | 2008-12-15 | Dextech Medical Ab | Muokatut hydroksipolymeerikonjugaatit, joilla on tappava vaikutus tuumorisoluihin |
| CA2926573C (en) * | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| MX2010011071A (es) | 2008-04-07 | 2010-11-12 | Dextech Medical Ab | Conjugados de hidroxipolimero modificados con porciones de localizacion osea y de destruccion tumoral. |
| PL2739316T3 (pl) * | 2011-08-05 | 2019-09-30 | Molecular Insight Pharmaceuticals, Inc. | Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty |
| CN107382890B (zh) * | 2011-11-30 | 2021-01-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| AU2013344778C1 (en) * | 2012-11-15 | 2024-06-27 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
| EP2958596B1 (en) * | 2013-02-15 | 2019-12-04 | Case Western Reserve University | Psma ligands and uses thereof |
| EP3057620A4 (en) * | 2013-10-18 | 2017-05-24 | Molecular Insight Pharmaceuticals, Inc. | Methods of using spect/ct analysis for staging cancer |
| CA2950892C (en) * | 2014-05-06 | 2023-10-24 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| EP3011976A1 (en) * | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
-
2016
- 2016-06-22 FI FI20165515A patent/FI127538B/en active IP Right Grant
-
2017
- 2017-06-19 IL IL263886A patent/IL263886B2/en unknown
- 2017-06-19 US US16/309,360 patent/US20190175767A1/en not_active Abandoned
- 2017-06-19 EP EP17734661.6A patent/EP3475311B1/en active Active
- 2017-06-19 CA CA3027920A patent/CA3027920C/en active Active
- 2017-06-19 JP JP2018566546A patent/JP6944720B2/ja active Active
- 2017-06-19 CN CN201780038758.6A patent/CN109312004A/zh active Pending
- 2017-06-19 AU AU2017283151A patent/AU2017283151A1/en not_active Abandoned
- 2017-06-19 WO PCT/EP2017/064929 patent/WO2017220488A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304588B2 (ja) | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 | |
| CN107382846B (zh) | Psma-结合剂及其用途 | |
| PH12020550898A1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| JP2017530184A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2008521928A5 (enExample) | ||
| NZ544583A (en) | Bicyclic peptide imaging agents for in vivo diagnosis or imaging of a disease or condition associated with angiogenesis | |
| JP2017530171A5 (enExample) | ||
| JP2014530852A5 (enExample) | ||
| JP2022501383A5 (enExample) | ||
| JP2021502415A5 (enExample) | ||
| JP2016503399A5 (enExample) | ||
| JP2014507412A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| JP2019509253A5 (enExample) | ||
| JP2019513829A5 (enExample) | ||
| MX2024009858A (es) | Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos | |
| RU2015117483A (ru) | Комбинации | |
| RU2016116915A (ru) | Комбинация | |
| IL272895B1 (en) | Therapeutic metal compounds and ligands and methods for their preparation and use | |
| JP2014129316A (ja) | 放射性医薬及び医薬キット | |
| JP2020514345A5 (enExample) | ||
| Kunikowska et al. | TeleNEN as a telemedicine model for neuroendocrine neoplasm management in case of Meckel’s diverticulum NET | |
| Tanha et al. | Radiotracer Accumulation in the Pyelocaliceal System of Transplanted Kidney: A Potential Pitfall in Lymphoscintigraphy of Pelvic Malignancies | |
| Class et al. | Patent application title: METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY |